Biosidus Expands Bioproduction Capacity in Argentina

Argentinian biotechnology company Biosidus has significantly expanded its production capacity with a new bioreactor facility. The firm, which has over 40 years of experience in developing and manufacturing biosimilar drugs, announced that the plant is now operational.

The new facility is located in Argentina and its expansion is intended to bolster the company's global supply capabilities. Specifically, the company mentioned an increased production of agalsidase beta, a medication used to treat Fabry disease.

Biosidus is recognized for its development and manufacturing of high-quality biosimilars. The company's strategy involves continuous investment in research and production expansion to meet global healthcare demands.

This enhanced production capacity supports Biosidus's objective to improve patient access to essential treatments worldwide. The company has not previously disclosed the investment size or the exact completion date of the facility.